Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production by irreversibly blocking the H+/K+ ATPase enzyme system in gastric parietal cells.
### Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis healing and maintenance, symptomatic GERD
* Zollinger-Ellison syndrome
* Part of H. pylori eradication regimens
### Adult Dosing
* **Erosive esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks.
* **Symptomatic GERD:** 20 mg orally once daily. May increase to 40 mg once daily if inadequate symptom control.
* **H. pylori eradication:** 40 mg orally twice daily in combination with antibiotics (e.g., amoxicillin and clarithromycin) for 7-14 days.
* **Zollinger-Ellison syndrome:** Start at 40 mg orally or intravenously once daily. Doses may be titrated up to 240 mg daily (divided into 2 doses) based on acid output.
### Pediatric Dosing
* **GERD (erosive esophagitis):**
* 1 year to less than 5 years: 10 mg orally once daily for up to 8 weeks.
* 5 years to 16 years: 20 mg orally once daily for up to 8 weeks.
* Higher doses may be considered in some cases, but efficacy and safety are less established.
* Dosing for H. pylori eradication and Zollinger-Ellison syndrome in pediatric patients is not well established.
### Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 20 mg orally or intravenously.
* **Renal Impairment:** No dose adjustment generally recommended.
### Contraindications
* Known hypersensitivity to pantoprazole, any component of the formulation, or other substituted benzimidazoles.
### Adverse Effects
* **Common:** Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence.
* **Long-term use (potential risks):** Increased risk of Clostridium difficile-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, vitamin B12 deficiency, and possibly increased risk of certain infections (e.g., pneumonia).
### Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Absorption may be decreased for drugs like ketoconazole, itraconazole, posaconazole, iron salts, and certain HIV protease inhibitors (e.g., atazanavir, nelfinavir). Separate administration by at least 12 hours.
* **Methotrexate:** Pantoprazole may increase serum levels of methotrexate, potentially leading to toxicity. Monitor closely.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. May affect metabolism of drugs like clopidogrel.
### Monitoring
* **For H. pylori eradication:** Confirm eradication with appropriate testing after treatment completion.
* **Long-term therapy:** Consider monitoring magnesium levels periodically, especially in patients on concomitant diuretic therapy or with other risk factors for hypomagnesemia. Assess for signs of vitamin B12 deficiency. Monitor for bone fracture risk factors.
### Clinical Pearls
* Pantoprazole is generally less potent than some other PPIs, but offers a favorable safety profile for many patients.
* Oral formulations should be taken at least 1 hour before a meal.
* Delayed-release granules for oral suspension should not be crushed or chewed.
* Intravenous administration should be followed by oral therapy when appropriate.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive prescribing information. Always consult the most current product labeling and relevant clinical guidelines before making any treatment decisions.
